杨芳;祭芬;黄吉娥;曾小菁;

• 1:贵阳医学院医学检验系临床血液学教研室
• 2:贵阳医学院附院血液科

摘要(Abstract)：

目的:探讨胃癌患者手术前后血浆PAI-1、t-PA含量变化及临床价值。方法:采用双抗体夹心酶标免疫分析法,测定胃癌患者手术前后血浆PAI-1、t-PA与肿瘤转移和预后的关系。结果:胃癌术前PAI-1、t-PA均与非肿瘤对照组差异有统计学意义(P<0.05),行胃癌根治术后t-PA水平较术前差异有统计学意义(P<0.05);胃癌患者转移和无转移者PAI-1水平有统计学差异,而t-PA变化不大(P>0.05)。结论:血浆PAI-1、t-PA水平与胃癌的浸润及转移过程密切相关。

关键词(KeyWords)： 胃癌;组织型纤溶酶原激活物;纤溶酶原激活物抑制剂;双抗体夹心酶标免疫分析法

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨芳;祭芬;黄吉娥;曾小菁;

Email:

DOI: 10.19367/j.cnki.1000-2707.2011.06.026

参考文献(References)：

• [1]Voland C,Serre CM,Delmzs P.Platelet-osteosarcoma cellinteraction is mediated through a specific fibrinogen-bindingsequence located within the N-terminal domain of throm-bospondin 1[J].J Boneminer Res,2000(2):361-368.
• [2]Gouin-Thibault I,Samama MM.Laboratory diagnosis ofthe thrombophilic state in cancer patients[J].SeminThromb Hemost,1999(2):167-172.
• [3]Chen GA,Feng Q,Zhang LZ,et al.Plasminogen acti-vators and plasminogen activator inhibitor type21 in hu-man endometrium[J].Chin J Physiol Sci,1992(2):150-157.
• [4]Macchione E,Ep ifano O,StefaniniM,et al.Urokinaseredistribution from the secreted to cell-bound fraction ingranulosa cells of rat p reovulatory follicles[J].Biol Reprod,2000(4):895-897.
• [5]Kurt B,Jan H akan J,Torb jorn N,et al.Effects ofcarve?dilol orm etopro lol on PAI-1,t-PA mass concentra tion or von Willebrand factor in chronic heart fa ilureaCOM ET sub study[J].Throm b Res,2010(2):46-50.
• [6]段朝霞,杨林花.凝血和纤维蛋白溶解系统与实体瘤静脉血栓形成及转移的相关研究[J].肿瘤研究与临床,2007(1):729-731.
• [7]Gerstein ES,Shcherbakov AI,Kazmin AI,et al.Uro-kinase and tissue type plasminogen activators and theirtype-1 inhibitor(PAI-1)in gastric cancer[J].VoprOnkol,2003(2):165-169.
• [8]Konno H,Abe J,Kaneko T,et al.Urokinase receptorand vascular endothelial growth factor are synergisticallyassociated with the live metastasis of colorectal cancer[J].Cancer Res,2001(5):516-523.
• [9]沈倩云,林建灿,孙义国,等.乳腺癌组织和血液中组织型纤溶酶原激活剂及其抑制剂测定的临床意义[J].中国肿瘤临床,1998(5):360-362.

文章评论(Comment)：